	US 11,926,677 B2
	Peptides and uses thereof for treating cancer
Chai Ezerzer, Ness Ziona (IL)
Assigned to SYMTHERA CANADA LTD., Ontario (CA)
Filed by SYMTHERA CANADA LTD., Ontario (CA)
Filed on Oct. 30, 2020, as Appl. No. 17/084,765.
Claims priority of provisional application 62/928,435, filed on Oct. 31, 2019.
Prior Publication US 2021/0188910 A1, Jun. 24, 2021
Int. Cl. C07K 7/06 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 7/06 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 7/08 (2013.01); C07K 14/001 (2013.01); A61K 38/00 (2013.01)]

17 Claims

1. A pharmaceutical composition comprising a cancer treating therapeutically effective amount of one or more cancer peptide agents consisting of an amino acid sequence selected from the group consisting of DVWSLGCILY (SEQ ID NO:6), DVWSIGCIMY (SEQ ID NO:7), DVWSMGILLY (SEQ ID NO:8), DIWSLGCLLY (SEQ ID NO:9), and DVWSLGCLLY (SEQ ID NO:14), and benzalkonium chloride.